{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T00:53:34Z","timestamp":1794185614430,"version":"4.8.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","aaojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ophtha.2024.06.013","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T01:02:16Z","timestamp":1719018136000},"page":"1377-1388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Phase 1 Study of JNJ-81201887 Gene Therapy in Geographic Atrophy Secondary to Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"131","author":[{"given":"Jeffrey S.","family":"Heier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael N.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Pepio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Shiraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7269-4981","authenticated-orcid":false,"given":"Jessica","family":"Ackert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Nida","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Csaky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2024.06.013_bib1","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2214-109X(20)30488-5","article-title":"The Lancet Global Health Commission on Global Eye Health: vision beyond 2020","volume":"9","author":"Burton","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.ophtha.2024.06.013_bib2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1471-2415-14-78","article-title":"The prevalence of anxiety and depression in people with age-related macular degeneration: a systematic review of observational study data","volume":"14","author":"Dawson","year":"2014","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.06.013_bib3","first-page":"591","article-title":"Depression in age-related macular degeneration","volume":"102","author":"Casten","year":"2008","journal-title":"J\u00a0Vis Impair Blind"},{"key":"10.1016\/j.ophtha.2024.06.013_bib4","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/IAE.0000000000001392","article-title":"The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target","volume":"37","author":"Boyer","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2024.06.013_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/OPTH.S367089","article-title":"Emerging treatment options for geographic atrophy (GA) secondary to age-related macular degeneration","volume":"17","author":"Khan","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.06.013_bib6","series-title":"Apellis Pharmaceuticals","year":"2023"},{"key":"10.1016\/j.ophtha.2024.06.013_bib8","series-title":"Patient and caregiver experience with anti-VEGF intravitreal injections to treat neovascular age-related macular degeneration and diabetic macular edema in the USA","author":"Holekamp","year":"2022"},{"key":"10.1016\/j.ophtha.2024.06.013_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.molimm.2014.06.032","article-title":"Genetic variants in the complement system predisposing to age-related macular degeneration: a review","volume":"61","author":"Schramm","year":"2014","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ophtha.2024.06.013_bib10","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41433-021-01765-x","article-title":"Complement cascade inhibition in geographic atrophy: a review","volume":"36","author":"Desai","year":"2022","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2024.06.013_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.molimm.2015.02.032","article-title":"Age-related macular degeneration and the role of the complement system","volume":"67","author":"McHarg","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.ophtha.2024.06.013_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019078","article-title":"A\u00a0non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration","volume":"6","author":"Cashman","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2024.06.013_bib13","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1167\/iovs.11-8425","article-title":"C9-R95X polymorphism in patients with neovascular age-related macular degeneration","volume":"53","author":"Nishiguchi","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2024.06.013_bib14","author":"Alekseev"},{"key":"10.1016\/j.ophtha.2024.06.013_bib15","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/s41467-023-36441-z","article-title":"Structural basis for membrane attack complex inhibition by CD59","volume":"14","author":"Couves","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ophtha.2024.06.013_bib16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/path.4128","article-title":"Decreased membrane complement regulators in the retinal pigmented epithelium contributes to age-related macular degeneration","volume":"229","author":"Ebrahimi","year":"2013","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.ophtha.2024.06.013_bib17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/2211-5463.13029","article-title":"The CAG promoter maintains high-level transgene expression in HEK293 cells","volume":"11","author":"Dou","year":"2021","journal-title":"FEBS Open Bio"},{"key":"10.1016\/j.ophtha.2024.06.013_bib18","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1167\/iovs.10-6250","article-title":"Intravitreal injection of AAV2 transduces macaque inner retina","volume":"52","author":"Yin","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.ophtha.2024.06.013_bib19","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.4049\/jimmunol.178.3.1783","article-title":"CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration","volume":"178","author":"Bora","year":"2007","journal-title":"J\u00a0Immunol"},{"issue":"9","key":"10.1016\/j.ophtha.2024.06.013_bib20","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1167\/iovs.08-2025","article-title":"Evaluation of adenovirus-delivered human CD59 as a potential therapy for AMD in a model of human membrane attack complex formation on murine RPE","volume":"49","author":"Ramo","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2024.06.013_bib21","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of Uveitis Nomenclature Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.06.013_bib22","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.ophtha.2024.06.013_bib23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/IIO.0000000000000366","article-title":"Ocular inflammation and treatment emergent adverse events in retinal gene therapy","volume":"61","author":"Mehta","year":"2021","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.ophtha.2024.06.013_bib24","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11095-018-2564-5","article-title":"Adeno-associated viral gene therapy for inherited retinal disease","volume":"36","author":"Ong","year":"2019","journal-title":"Pharm Res"},{"key":"10.1016\/j.ophtha.2024.06.013_bib25","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 trial","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.06.013_bib26","series-title":"24-month safety results from the OAKS and DERBY trials with further characterization of exudative age-related macular degeneration","author":"Ferrone","year":"2023"},{"key":"10.1016\/j.ophtha.2024.06.013_bib27","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/archophthalmol.2009.198","article-title":"Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26","volume":"127","author":"Lindblad","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.06.013_bib28","first-page":"S3","article-title":"Optimizing anti-VEGF treatment outcomes for patients with neovascular age-related macular degeneration","volume":"24","author":"Wykoff","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.ophtha.2024.06.013_bib29","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024003683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024003683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T21:24:14Z","timestamp":1736457854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642024003683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0161642024003683"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.06.013","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1 Study of JNJ-81201887 Gene Therapy in Geographic Atrophy Secondary to Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}